Wedbush Securities Inc. Purchases New Stake in United Therapeutics Corporation (UTHR)

Wedbush Securities Inc. purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,710 shares of the biotechnology company’s stock, valued at approximately $435,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Eagle Global Advisors LLC acquired a new stake in shares of United Therapeutics Corporation during the second quarter worth about $206,000. TLP Group LLC acquired a new stake in United Therapeutics Corporation in the 2nd quarter valued at approximately $246,000. HPM Partners LLC raised its position in United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 15 shares during the last quarter. Fort L.P. raised its position in United Therapeutics Corporation by 5.2% in the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after buying an additional 99 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in United Therapeutics Corporation by 4.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 95 shares during the last quarter.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 2,176 shares of United Therapeutics Corporation stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $127.11, for a total value of $276,591.36. Following the completion of the transaction, the chief executive officer now directly owns 3,245 shares of the company’s stock, valued at approximately $412,471.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,235 shares of United Therapeutics Corporation stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $131.95, for a total value of $162,958.25. Following the completion of the transaction, the chief executive officer now directly owns 2,304 shares of the company’s stock, valued at $304,012.80. The disclosure for this sale can be found here. Insiders sold a total of 18,389 shares of company stock valued at $2,287,452 over the last 90 days. 7.80% of the stock is currently owned by corporate insiders.

UTHR has been the topic of a number of recent research reports. Zacks Investment Research raised United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. ValuEngine raised United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. HC Wainwright reissued a “hold” rating and issued a $95.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, October 26th. Jefferies Group LLC reissued a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research report on Friday, July 14th. Finally, Cowen and Company reissued a “hold” rating and issued a $129.00 target price on shares of United Therapeutics Corporation in a research report on Friday, October 27th. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average price target of $132.82.

WARNING: This piece was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/06/wedbush-securities-inc-purchases-new-stake-in-united-therapeutics-corporation-uthr.html.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at $120.95 on Monday. The stock has a market capitalization of $5,226.38, a price-to-earnings ratio of 10.67 and a beta of 1.38. United Therapeutics Corporation has a one year low of $112.01 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $4.23 EPS. equities analysts forecast that United Therapeutics Corporation will post 11.92 EPS for the current year.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit